

# Global Vascular Endothelial Growth Factor Receptor (VEGFR) Inhibitors Market - 2024-2033

<https://marketpublishers.com/r/G4979B1B30CFEN.html>

Date: November 2025

Pages: 207

Price: US\$ 2,999.00 (Single User License)

ID: G4979B1B30CFEN

## Abstracts

The Global Vascular Endothelial Growth Factor Receptor (VEGFR) Inhibitors Market was valued at US\$ 14.12 billion in 2024 and is anticipated to reach US\$ 22.34 billion by 2033, at a CAGR of 0.059 from 2026 to 2032.

The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms of both value and volume, along with emerging opportunities and the overall development outlook of the Global Vascular Endothelial Growth Factor Receptor (VEGFR) Inhibitors Market.

This report delivers a comprehensive overview of the Global Vascular Endothelial Growth Factor Receptor (VEGFR) Inhibitors Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Global Vascular Endothelial Growth Factor Receptor (VEGFR) Inhibitors Market. The Global Vascular Endothelial Growth Factor Receptor (VEGFR) Inhibitors Market size, estimates, and forecasts are provided in terms of output/shipments (K MT) and revenue (US\$ millions), with 2025 as the base year and historical and forecast data for 2024–2033.

Global Vascular Endothelial Growth Factor Receptor (VEGFR) Inhibitors Market Scope:

By Type

VEGF-A

VEGF-B

VEGF-C

VEGF-D

### By Drug Type

Tyrosine Kinase Inhibitor (TKI)

Monoclonal Antibody

### By Application

Advanced Renal Cell Carcinoma

Advanced Colorectal Cancer

Metastatic Colorectal Cancer (mCRC)

Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Recurrent Glioblastoma (rGBM)

Ovarian Cancer (OC)

Hepatocellular Carcinoma

Thyroid cancer

Non-Small Cell Lung Cancer (NSCLC)

Wet Age-Related Macular Degeneration (AMD)

Diabetic Macular Edema (DME)

Retinal Vein Occlusion (RVO)

Others

#### By Route of Administration

Oral

Intravenous

Intravitreal

#### Key Players

Novartis AG

F. Hoffmann-La Roche Ltd

Amgen Inc.

Pfizer Inc.

Biocon

Exelixis, Inc.

Bayer AG

Eisai Co., Ltd.

Takeda Pharmaceuticals U.S.A., Inc.

Sanofi (Regeneron Pharmaceuticals, Inc.)

AVEO Pharmaceuticals, Inc.

Eli Lilly and Company

Genentech USA, Inc.

## Major Highlights

This report delivers a comprehensive overview of the Global Vascular Endothelial Growth Factor Receptor (VEGFR) Inhibitors Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Global Vascular Endothelial Growth Factor Receptor (VEGFR) Inhibitors Market. The Global Vascular Endothelial Growth Factor Receptor (VEGFR) Inhibitors Market size, estimates, and forecasts are provided in terms of output/shipments (K Sqm) and revenue (US\$ millions), with 2025 as the base year and historical and forecast data for 2024–2033.

This report will assist keyword manufacturers, new entrants, and companies across the industry value chain with information on revenues, production, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.

## Regional Analysis:

North America (U.S., Canada, Mexico)

Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

South America (Colombia, Brazil, Argentina, Rest of South America)

Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

## Partner Identification

Increase Your Customer Base by 3X using our Partner Identification tool

Uncover strategic collaboration opportunities with DataM vetted partners aligned to your ecosystem.

Identify high potential M&A targets based on synergies, market positioning and growth trajectory.

Prioritize partners by strategic fit rather than general capability.

## Why Choose DataM?

**Data-Driven Insights:** Dive into detailed analyses with granular insights such as pricing, market shares and value chain evaluations, enriched by interviews with industry leaders and disruptors.

**Post-Purchase Support and Expert Analyst Consultations:** As a valued client, gain direct access to our expert analysts for personalized advice and strategic guidance, tailored to your specific needs and challenges.

**White Papers and Case Studies:** Benefit quarterly from our in-depth studies related to your purchased titles, tailored to refine your operational and marketing strategies for maximum impact.

**Annual Updates on Purchased Reports:** As an existing customer, enjoy the privilege of annual updates to your reports, ensuring you stay abreast of the latest market insights and technological advancements. Terms and conditions apply.

**Specialized Focus on Emerging Markets:** DataM differentiates itself by delivering in-depth, specialized insights specifically for emerging markets, rather than offering generalized geographic overviews. This approach equips our clients with a nuanced understanding and actionable intelligence that are essential for navigating and succeeding in high-growth regions.

**Value of DataM Reports:** Our reports offer specialized insights tailored to the latest trends and specific business inquiries. This personalized approach provides a deeper, strategic perspective, ensuring you receive the precise

information necessary to make informed decisions. These insights complement and go beyond what is typically available in generic databases.

### Target Audience 2026

Manufacturers/ Buyers

Industry Investors/Investment Bankers

Research Professionals

Emerging Companies

## Contents

### 1. METHODOLOGY AND SCOPE

- 1.1. Research Methodology
- 1.2. Research Objective and Scope of the Report

### 2. DEFINITION AND OVERVIEW

### 3. EXECUTIVE SUMMARY

- 3.1. Snippet by Type
- 3.2. Snippet by Drug Type
- 3.3. Snippet by Application
- 3.4. Snippet by Route of Administration
- 3.5. Snippet by Region

### 4. DYNAMICS

- 4.1. Impacting Factors
  - 4.1.1. Drivers
    - 4.1.1.1. Rising Incidence and Prevalence of Cancer
    - 4.1.1.2. Advancements in Drug Development & Biosimilars
    - 4.1.1.3. XX
  - 4.1.2. Restraints
    - 4.1.2.1. High Cost of Treatment
    - 4.1.2.2. Adverse Side Effects Associated with the Treatment
    - 4.1.2.3. XX
  - 4.1.3. Opportunity
    - 4.1.3.1. Technological Advancements and Combination Therapies
    - 4.1.3.2. XX

### 5. IMPACT ANALYSIS

### 6. STRATEGIC INSIGHTS AND INDUSTRY OUTLOOK

- 6.1. Market Leaders and Pioneers
  - 6.1.1. Emerging Pioneers and Prominent Players
  - 6.1.2. Established leaders with largest selling Brand

- 6.1.3. Market leaders with established Product
- 6.2. CXO Perspectives
- 6.3. Latest Developments and Breakthroughs
- 6.4. Case Studies/Ongoing Research
- 6.5. Regulatory and Reimbursement Landscape
  - 6.5.1. North America
  - 6.5.2. Europe
  - 6.5.3. Asia Pacific
  - 6.5.4. Latin America
  - 6.5.5. Middle East & Africa
- 6.6. Porter's Five Forces Analysis
- 6.7. Supply Chain Analysis
- 6.8. Patent Analysis
- 6.9. SWOT Analysis
- 6.10. Unmet Needs and Gaps
- 6.11. Recommended Strategies for Market Entry and Expansion
- 6.12. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
- 6.13. Pricing Analysis and Price Dynamics
- 6.14. Key Opinion Leaders

## **7. BY TYPE**

- 7.1. Introduction
  - 7.1.1. Analysis and Y-o-Y Growth Analysis (%), By Type
  - 7.1.2. Market Attractiveness Index By Type
- 7.2. VEGF-A\*
  - 7.2.1. Introduction
  - 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 7.3. VEGF-B
- 7.4. VEGF-C
- 7.5. VEGF-D

## **8. BY DRUG TYPE**

- 8.1. Introduction
  - 8.1.1. Analysis and Y-o-Y Growth Analysis (%), By Drug Type
  - 8.1.2. Market Attractiveness Index By Drug Type
- 8.2. Tyrosine Kinase Inhibitor (TKI)\*
  - 8.2.1. Introduction

### 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)

#### 8.2.3. Pazopanib

#### 8.2.4. Sunitinib Malate

#### 8.2.5. Cabozantinib

#### 8.2.6. Sorafenib

#### 8.2.7. Lenvatinib

#### 8.2.8. Regorafenib

#### 8.2.9. Axitinib

#### 8.2.10. Ponatinib

#### 8.2.11. Tivozanib

#### 8.2.12. Others

### 8.3. Monoclonal Antibody

#### 8.3.1. Bevacizumab

#### 8.3.2. Brolucizumab

#### 8.3.3. Ramucirumab

#### 8.3.4. Ranibizumab

#### 8.3.5. Faricimab

#### 8.3.6. Others

## 9. BY APPLICATION

### 9.1. Introduction

#### 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application

#### 9.1.2. Market Attractiveness Index By Application

### 9.2. Advanced Renal Cell Carcinoma\*

#### 9.2.1. Introduction

#### 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)

### 9.3. Advanced Colorectal Cancer

### 9.4. Metastatic Colorectal Cancer (mCRC)

### 9.5. Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

### 9.6. Recurrent Glioblastoma (rGBM)

### 9.7. Ovarian Cancer (OC)

### 9.8. Hepatocellular Carcinoma

### 9.9. Thyroid cancer

### 9.10. Non-Small Cell Lung Cancer (NSCLC)

### 9.11. Wet Age-Related Macular Degeneration (AMD)

### 9.12. Diabetic Macular Edema (DME)

### 9.13. Retinal Vein Occlusion (RVO)

### 9.14. Others

## **10. BY ROUTE OF ADMINISTRATION**

### 10.1. Introduction

10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration

10.1.2. Market Attractiveness Index By Route of Administration

### 10.2. Oral\*

10.2.1. Introduction

10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)

### 10.3. Intravenous

### 10.4. Intravitreal

## **11. BY REGION**

### 11.1. Introduction

11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region

11.1.2. Market Attractiveness Index, By Region

### 11.2. North America

11.2.1. Introduction

11.2.2. Key Region-Specific Dynamics

11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type

11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type

11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application

11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration

11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

11.2.7.1. U.S.

11.2.7.2. Canada

### 11.3. Europe

11.3.1. Introduction

11.3.2. Key Region-Specific Dynamics

11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type

11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type

11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application

11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration

11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

11.3.7.1. Germany

11.3.7.2. U.K.

11.3.7.3. France

11.3.7.4. Spain

11.3.7.5. Italy

11.3.7.6. Rest of Europe

11.4. Latin America

11.4.1. Introduction

11.4.2. Key Region-Specific Dynamics

11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type

11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type

11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application

11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration

11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

11.4.7.1. Mexico

11.4.7.2. Brazil

11.4.7.3. Argentina

11.4.7.4. Rest of Latin America

11.5. Asia-Pacific

11.5.1. Introduction

11.5.2. Key Region-Specific Dynamics

11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type

11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type

11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application

11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration

11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

11.5.7.1. China

11.5.7.2. India

11.5.7.3. Japan

11.5.7.4. South Korea

11.5.7.5. Rest of Asia-Pacific

11.6. Middle East and Africa

11.6.1. Introduction

11.6.2. Key Region-Specific Dynamics

11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type

11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type

11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application

11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of

Administration

## **12. COMPETITIVE LANDSCAPE**

- 12.1. Competitive Scenario
- 12.2. Market Positioning/Share Analysis
- 12.3. Mergers and Acquisitions Analysis

## **13. COMPANY PROFILES**

- 13.1. Novartis AG\*
  - 13.1.1. Company Overview
  - 13.1.2. Product Portfolio
    - 13.1.2.1. Product Description
    - 13.1.2.2. Product Key Performance Indicators (KPIs)
    - 13.1.2.3. Historic and Forecasted Product Sales
    - 13.1.2.4. Product Sales Volume
  - 13.1.3. Financial Overview
    - 13.1.3.1. Company Revenue's
    - 13.1.3.2. Geographical Revenue Shares
    - 13.1.3.3. Revenue Forecasts
  - 13.1.4. Key Developments
    - 13.1.4.1. Mergers & Acquisitions
    - 13.1.4.2. Key Product Development Activities
    - 13.1.4.3. Regulatory Approvals, etc.
  - 13.1.5. SWOT Analysis
- 13.2. F. Hoffmann-La Roche Ltd
- 13.3. Amgen Inc.
- 13.4. Pfizer Inc.
- 13.5. Biocon
- 13.6. Exelixis, Inc.
- 13.7. Bayer AG
- 13.8. Eisai Co., Ltd.
- 13.9. Takeda Pharmaceuticals U.S.A., Inc.
- 13.10. Sanofi (Regeneron Pharmaceuticals, Inc.)
- 13.11. AVEO Pharmaceuticals, Inc.
- 13.12. Eli Lilly and Company
- 13.13. Genentech USA, Inc. (LIST NOT EXHAUSTIVE)

## **14. APPENDIX**

14.1. About Us and Services

14.2. Contact Us

## I would like to order

Product name: Global Vascular Endothelial Growth Factor Receptor (VEGFR) Inhibitors Market - 2024-2033

Product link: <https://marketpublishers.com/r/G4979B1B30CFEN.html>

Price: US\$ 2,999.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G4979B1B30CFEN.html>